Research ArticleInfectious Disease

IVIG-mediated protection against necrotizing pneumonia caused by MRSA

See allHide authors and affiliations

Science Translational Medicine  21 Sep 2016:
Vol. 8, Issue 357, pp. 357ra124
DOI: 10.1126/scitranslmed.aag1153

Stemming the tide of MRSA-induced pneumonia

Controversies persist about the use of human intravenous immunoglobulin (IVIG) as an adjunctive treatment for severe Staphylococcus aureus pneumonia because empirical evidence supporting its use is lacking. Diep and colleagues now show that, of the myriad antibodies contained in IVIG, only two specific antibodies that neutralize the toxic effects of α-hemolysin (Hla) and Panton-Valentine leukocidin (PVL) are necessary and sufficient to confer protection against necrotizing pneumonia caused by MRSA in a rabbit model. Preexposure prophylaxis with IVIG, or postexposure treatment with IVIG in combination with either vancomycin or linezolid, improved survival outcomes in this preclinical animal model.